Table: Santen Pharm -9-MTH group results (IFRS)
05/02/2019 06:00
Feb 5 (Reuters)-
Santen Pharmaceutical Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
9 months ended 9 months ended Year to
Dec 31, 2018 Dec 31, 2017 Mar 31, 2019
LATEST YEAR-AGO COMPANY
RESULTS RESULT FORECAST
Sales 173.21 168.59 237.00
(+2.7 pct) (+11.9 pct) (+5.4 pct)
Operating 33.66 30.09 40.70
(+11.9 pct) (+9.5 pct) (+5.2 pct)
Pretax 32.41 29.54 41.30
(+9.7 pct) (+23.5 pct) (+5.2 pct)
Net 23.38 27.33
(-14.5 pct) (+59.2 pct)
EPS Basic 57.44 yen 67.27 yen 75.21 yen
EPS Diluted 57.26 yen 67.02 yen
Ann Div 26.00 yen 26.00 yen
-Q2 Div 13.00 yen 13.00 yen
-Q4 Div 13.00 yen 13.00 yen
NOTE - Santen Pharmaceutical Co Ltd.
(Figures are reported based on international accounting rules (IFRS).)
If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half
dividend and Q4 to the second-half dividend announced before a new corporate law in
2006 allowed companies to pay and report dividends on a quarterly basis.
*Net - represents Net profit attributable to owners of the parent company.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4536.T